Webinars
Discover innovation and expertise with our webinar series. Choose from three formats: Product Insights (learn about Olink’s products in depth), Application Focus (see how customers use Olink technology to advance their research), and Technical Proficiency (hosted by our expert support team with practical tips and strategies).
Filters
| Webinar | Application | Type | Products |
|---|---|---|---|
Technical Webinar: Unlock the full potential of your research with Olink’s bridging normalizationJoin our technical experts for a deep dive into normalization strategies, showcase real-world examples, and offer practical solutions to maximize the power of your studies. | Products | ||
Uncovering Proteomic Biomarkers Linking Type 2 Diabetes to Cardiovascular RiskCardiovascular expert Prof. Karol Kaminski, MD, PhD, presents a study that identified proteomic biomarkers in individuals with untreated glucose metabolism disturbances who are not diagnosed with diabetes, chronic inflammatory, neoplastic, or cardiovascular disease. | Products | ||
A Complete Solution for Identifying Protein Signatures: From Sample to Actionable ResultsExplore how the Olink® Signature Q100 benchtop system and NPX Signature software are part of a complete solution for generating meaningful protein signatures, from study design to data interpretation. | Products | ||
The Proteomics Frontier Webinar Series: Transforming Neurology and Driving Precision MedicineDive into the transformative power of Olink's proteomics platform and its revolutionary impact on neurological research and precision medicine. Learn how large-scale protein studies are unlocking the secrets of neurological disorders and revolutionizing medicine. | Products | ||
Technical Webinar: Study design considerations when running alternative matricesJoin our technical experts for a deep dive into study design considerations for Olink projects using alternative matrices. | Products | ||
Using NGS-Based Proteomics to Differentiate BTK Inhibitor Response in LeukemiaThis webinar will highlight a study that compares the effect of three different BTK inhibitors: ibrutinib, acalabrutinib, and zanubrutinib. Patient samples were obtained before and at various time points after treatment to identify biomarkers that could be informative of the treatment’s effects. | Products | ||
Immune-competent vascularized human cerebral organoids to study brain development and disease: a multiomics approachThe Network Biology Collaborative Centre at Mount Sinai Hospital, an Olink Certified Service Provider, present their application of Olink’s Proximity Extension Assay technology to profile an organoid-based model that provides novel regulatory and mechanistic insights into human brain development. | Products | ||
Advancing proteomics in clinical research with the combined strengths of mass spectrometry and affinity-based methodsA roundtable discussion between key opinion leaders in proteomics explores how integrating antibody-based methods, like proximity extension assay (PEA), with LC-MS can expand proteome coverage, facilitate biomarker discovery, and streamline the validation process. | Products | ||
Charting the Future of Mental Health Precision Medicine with ProteomicsResults from a proteomics pilot study exploring biomarkers associated with postpartum depression (PPD) using Olink Explore HT. This research investigated a cohort of 50 mothers diagnosed with PPD, focusing on discovering proteins that may serve as unique biomarkers for early detection and treatment. | Products | ||
Affinity Proteomics and LC-MS synergize Biomarker DiscoveryOlink Certified Service Provider, Discovery Life Sciences, compares cutting-edge technology to study the proteome in liquid matrices. | Products | ||
Integrating plasma proteomics to identify tuberculosis-specific diagnostic biomarkersUsing mass spectrometry, Olink’s proximity extension assay, cross-disciplinary research, and international collaboration, Dr. Schiff and team have identified protein biomarkers with high TB-specificity and demonstrated the diagnostic performance of a six-protein diagnostic panel. | Products | ||
Exploring molecular phenotypes of incident breast cancer through population-based proteogenomicsAnders Mälarstig, Director of Target Sciences at Pfizer, presents the integration of multi-omics for cancer prevention, large-scale proteomics analyses, and the use of high-throughput proteomics to identify actionable biomarkers for improved cancer diagnosis and treatment. | Products | ||
What is a Good Biomarker?Olink experts review the critical role of protein biomarkers in advancing personalized medicine, the challenges and opportunities of the protein biomarker development pipeline, and how PEA is facilitating the journey from discovery to clinical utility while delivering reproducible insights. | Products | ||
Maternal inflammation during pregnancy and risk of immune-mediated diseases in birth cohortsJonathan Thorsen, MD Ph.D., Senior Researcher at COPSAC, presents a webinar on the HEDIMED project, which analyzed perinatal blood samples from four northern European birth cohorts to identify immune markers for childhood diseases, using the Olink Target96 Inflammation platform. | Products | ||
Circulating inflammatory biomarkers associated with cognitive function and dementiaDr. Margaret Doyle examines inflammation's role in cognitive decline and Alzheimer's using Olink proteomics, identifying key inflammatory biomarkers and their associations with cognitive domains in the Framingham Heart Study. | Products | ||
Detecting Cancer Biomarkers from Proteins in Liquid BiopsiesJoin Klaus Pantel, Chairman and Founding Director, Institute for Tumor Biology, and Christoffer Gebhardt, Head, university Skin Cancer Center, Hamburg, as they discuss the role of circulating protein biomarkers, technological advancements, and clinical applications in implementing liquid biopsy. | Products | ||
The right drug targets for the right patient – Using biomarkers to solve challenges in drug developmentDr. Jürgen Braunger of Boehringer Ingelheim Pharma, Dr. Timothy Radstake of AbbVie and Dr. Christopher D. Whelan of Biogen discuss clinical trials, current practices, historical context, and future challenges. Learn how protein markers enhance patient stratification by disease severity. | Products | ||
Identification of predictive biomarkers of immunotherapy efficacy in cancer patients through analysis of plasma proteomicsProfessor Antoine Italiano (Head of Early Phase Trials and Sarcoma Unit, Institut Bergonié) presents how protein biomarkers are providing an improve understanding and characterization of cancer patients stratification within Immuno-Oncology. | Products | ||
Protein biomarkers in plasma: revealing biological insights into tumor microenvironmentThis webinar explore how an extensive plasma proteomic analysis revealed biological insights about the tumor microenvironment in melanoma patients after immune checkpoint blockade and helped them to identify composite biomarkers to better predict sensitivity and response to immunotherapy. | Products | ||
Driving Next-generation medicine discovery: exposing causal biomarker-disease relationships using proteomicsSpeakers from SCALLOP discuss how enabling technologies are allowing proteogenomic studies to be performed on a scale not previously possible, and will provide examples of such studies, including one assessing links between angiotensin-converting enzyme 2 (ACE2) expression and COVID-19. | Products |